These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 25203856)

  • 1. The critical role of bisphosphonates to target bone cancer metastasis: an overview.
    Singh T; Kaur V; Kumar M; Kaur P; Murthy RS; Rawal RK
    J Drug Target; 2015 Jan; 23(1):1-15. PubMed ID: 25203856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates: the first 40 years.
    Russell RG
    Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New role for an established drug? Bisphosphonates as potential anticancer agents.
    Koul HK; Koul S; Meacham RB
    Prostate Cancer Prostatic Dis; 2012 Jun; 15(2):111-9. PubMed ID: 21876554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effects of bisphosphonates.
    Green JR
    Cancer; 2003 Feb; 97(3 Suppl):840-7. PubMed ID: 12548584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates: preclinical review.
    Green JR
    Oncologist; 2004; 9 Suppl 4():3-13. PubMed ID: 15459425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumour activity of zoledronic acid.
    Clézardin P
    Cancer Treat Rev; 2005; 31 Suppl 3():1-8. PubMed ID: 16225995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The backbone of progress--preclinical studies and innovations with zoledronic acid.
    Green JR; Guenther A
    Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S3-S12. PubMed ID: 21353178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.
    Boissier S; Ferreras M; Peyruchaud O; Magnetto S; Ebetino FH; Colombel M; Delmas P; Delaissé JM; Clézardin P
    Cancer Res; 2000 Jun; 60(11):2949-54. PubMed ID: 10850442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonates: new therapeutic agents for the treatment of bone tumors.
    Heymann D; Ory B; Gouin F; Green JR; Rédini F
    Trends Mol Med; 2004 Jul; 10(7):337-43. PubMed ID: 15242682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antitumor potential of bisphosphonates.
    Clézardin P
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):33-42. PubMed ID: 12584693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway.
    Virtanen SS; Väänänen HK; Härkönen PL; Lakkakorpi PT
    Cancer Res; 2002 May; 62(9):2708-14. PubMed ID: 11980672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention.
    Lipton A
    J Support Oncol; 2004; 2(3):205-13; discussion 213-4, 216-7, 219-20. PubMed ID: 15328823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-tumor potential of bisphosphonates.
    Green JR
    Med Klin (Munich); 2000 Oct; 95 Suppl 2():23-8. PubMed ID: 11089384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors.
    Van Beek ER; Löwik CW; Papapoulos SE
    Bone; 2002 Jan; 30(1):64-70. PubMed ID: 11792566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonates modulate vital functions of human osteoblasts and affect their interactions with breast cancer cells.
    Kaiser T; Teufel I; Geiger K; Vater Y; Aicher WK; Klein G; Fehm T
    Breast Cancer Res Treat; 2013 Jul; 140(1):35-48. PubMed ID: 23807419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitrogen-containing bisphosphonate mechanism of action.
    Reszka AA; Rodan GA
    Mini Rev Med Chem; 2004 Sep; 4(7):711-9. PubMed ID: 15379639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment.
    Mundy GR; Yoneda T; Hiraga T
    Semin Oncol; 2001 Apr; 28(2 Suppl 6):35-44. PubMed ID: 11346863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of bisphosphonates in patients with metastatic bone disease.
    Berenson JR; Lipton A
    Oncology (Williston Park); 1998 Nov; 12(11):1573-9; discussion 1579-81. PubMed ID: 9834935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
    Russell RG; Xia Z; Dunford JE; Oppermann U; Kwaasi A; Hulley PA; Kavanagh KL; Triffitt JT; Lundy MW; Phipps RJ; Barnett BL; Coxon FP; Rogers MJ; Watts NB; Ebetino FH
    Ann N Y Acad Sci; 2007 Nov; 1117():209-57. PubMed ID: 18056045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.